Sage Mountain Advisors LLC Raises Position in AbbVie Inc. $ABBV

Sage Mountain Advisors LLC lifted its stake in AbbVie Inc. (NYSE:ABBV) by 20.1% in the 3rd quarter, HoldingsChannel reports. The firm owned 17,549 shares of the company’s stock after acquiring an additional 2,934 shares during the period. Sage Mountain Advisors LLC’s holdings in AbbVie were worth $4,063,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently bought and sold shares of the company. Norges Bank purchased a new position in shares of AbbVie during the 2nd quarter valued at about $4,288,200,000. Laurel Wealth Advisors LLC lifted its holdings in AbbVie by 18,384.4% during the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after purchasing an additional 5,675,095 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of AbbVie by 1.9% in the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock worth $32,910,186,000 after purchasing an additional 3,380,842 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in shares of AbbVie by 169.3% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock worth $876,662,000 after purchasing an additional 2,969,202 shares in the last quarter. Finally, Raymond James Financial Inc. raised its position in shares of AbbVie by 41.8% during the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after purchasing an additional 2,753,312 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ABBV. JPMorgan Chase & Co. upped their target price on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Hsbc Global Res raised AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, December 10th. UBS Group reissued a “neutral” rating on shares of AbbVie in a research note on Tuesday, January 13th. Raymond James Financial set a $256.00 price target on AbbVie in a research note on Monday, November 3rd. Finally, Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $248.11.

AbbVie Price Performance

Shares of ABBV opened at $212.32 on Tuesday. The business’s 50 day simple moving average is $226.72 and its 200-day simple moving average is $216.82. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The stock has a market capitalization of $375.24 billion, a price-to-earnings ratio of 160.84, a price-to-earnings-growth ratio of 0.88 and a beta of 0.36.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the business posted $3.00 earnings per share. AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is 524.24%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.